<SEC-DOCUMENT>0001213900-26-079393-index.html : 20260720
<SEC-HEADER>0001213900-26-079393.hdr.sgml : 20260720
<ACCEPTANCE-DATETIME>20260720070022
ACCESSION NUMBER:		0001213900-26-079393
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20260720
FILED AS OF DATE:		20260720
DATE AS OF CHANGE:		20260720

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAMADA LTD
		CENTRAL INDEX KEY:			0001567529
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35948
		FILM NUMBER:		261185141

	BUSINESS ADDRESS:	
		STREET 1:		2 HOLTZMAN ST., SCIENCE PARK
		CITY:			REHOVOT
		STATE:			L3
		ZIP:			7670402
		BUSINESS PHONE:		97289406472

	MAIL ADDRESS:	
		STREET 1:		2 HOLTZMAN ST., SCIENCE PARK
		CITY:			REHOVOT
		STATE:			L3
		ZIP:			7670402
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0298498-6k_kamada.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
Document 1 - file: ea0298498-6k_kamada.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea029849801ex99-1.htm
<DESCRIPTION>KAMADA ANNOUNCES A THREE-YEAR $50 MILLION SALES AGREEMENT TO SUPPLY PLASMA TO A LEADING BIOPHARMACEUTICAL COMPANY FOCUSED ON PLASMA-DERIVED THERAPIES
<TEXT>
Document 2 - file: ea029849801ex99-1.htm

</DOCUMENT>
</SEC-DOCUMENT>